DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy
Nemec AA, Abriola L, Merkel JS, de Stanchina E, DeVeaux M, Zelterman D, Glazer PM, Sweasy JB. DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy. Molecular Cancer Research 2017, 15: 269-280. PMID: 28074003, PMCID: PMC5334281, DOI: 10.1158/1541-7786.mcr-16-0227-t.Peer-Reviewed Original ResearchMeSH KeywordsA549 CellsAnimalsAntineoplastic AgentsCisplatinDNA Mismatch RepairDNA Polymerase betaDrug Resistance, NeoplasmGerm-Line MutationHCT116 CellsHumansMCF-7 CellsMiceNeoplasmsXenograft Model Antitumor AssaysConceptsPrognostic biomarker potentialMouse xenograft modelLung cancer cellsPoor prognosisTreatment of cancerLung cancerSpecific chemotherapyXenograft modelPromising biomarkerMouse xenograftsMutational statusCancer ResChemotherapyGermline mutationsNucleotide excision repair pathwayBiomarker potentialCancer chemotherapyCancer treatmentCarrier statusCisplatinCancer cellsTumorsCancerTreatmentCell death